全文获取类型
| 收费全文 | 1606425篇 |
| 免费 | 117517篇 |
| 国内免费 | 3394篇 |
专业分类
| 耳鼻咽喉 | 19908篇 |
| 儿科学 | 53764篇 |
| 妇产科学 | 44702篇 |
| 基础医学 | 222677篇 |
| 口腔科学 | 39447篇 |
| 临床医学 | 139627篇 |
| 内科学 | 319518篇 |
| 皮肤病学 | 34553篇 |
| 神经病学 | 134621篇 |
| 特种医学 | 63418篇 |
| 外国民族医学 | 464篇 |
| 外科学 | 244049篇 |
| 综合类 | 35520篇 |
| 现状与发展 | 3篇 |
| 一般理论 | 506篇 |
| 预防医学 | 128538篇 |
| 眼科学 | 34516篇 |
| 药学 | 109538篇 |
| 1篇 | |
| 中国医学 | 3999篇 |
| 肿瘤学 | 97967篇 |
出版年
| 2021年 | 11341篇 |
| 2019年 | 12047篇 |
| 2018年 | 39150篇 |
| 2017年 | 30592篇 |
| 2016年 | 35072篇 |
| 2015年 | 17322篇 |
| 2014年 | 23801篇 |
| 2013年 | 34704篇 |
| 2012年 | 52950篇 |
| 2011年 | 69947篇 |
| 2010年 | 47236篇 |
| 2009年 | 39261篇 |
| 2008年 | 65479篇 |
| 2007年 | 71351篇 |
| 2006年 | 48585篇 |
| 2005年 | 49303篇 |
| 2004年 | 48587篇 |
| 2003年 | 48043篇 |
| 2002年 | 44264篇 |
| 2001年 | 73579篇 |
| 2000年 | 75382篇 |
| 1999年 | 61968篇 |
| 1998年 | 17370篇 |
| 1997年 | 15838篇 |
| 1996年 | 15806篇 |
| 1995年 | 15004篇 |
| 1994年 | 13642篇 |
| 1993年 | 12795篇 |
| 1992年 | 46041篇 |
| 1991年 | 43741篇 |
| 1990年 | 41739篇 |
| 1989年 | 39767篇 |
| 1988年 | 36374篇 |
| 1987年 | 35556篇 |
| 1986年 | 33030篇 |
| 1985年 | 31462篇 |
| 1984年 | 23954篇 |
| 1983年 | 20157篇 |
| 1982年 | 12372篇 |
| 1981年 | 10876篇 |
| 1979年 | 20869篇 |
| 1978年 | 14702篇 |
| 1977年 | 12159篇 |
| 1976年 | 11465篇 |
| 1975年 | 11659篇 |
| 1974年 | 14057篇 |
| 1973年 | 13573篇 |
| 1972年 | 12671篇 |
| 1971年 | 11502篇 |
| 1970年 | 10970篇 |
排序方式： 共有10000条查询结果，搜索用时 281 毫秒
171.
Fabrice Barlesi Edward B. Garon Dong-Wan Kim Enriqueta Felip Ji-Youn Han Joo-Hang Kim Myung-Ju Ahn Mary Jo Fidler Matthew A. Gubens Gilberto de Castro Veerle Surmont Qiao Li Anne C. Deitz Gregory M. Lubiniecki Roy S. Herbst 《Journal of thoracic oncology》2019,14(5):793-801
Introduction
In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.Methods
Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.Results
Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.Conclusions
These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population. 相似文献172.
173.
174.
Victoria A. Chang Dawn M. Meyer Brett C. Meyer 《Journal of stroke and cerebrovascular diseases》2019,28(1):163-166
Background
Acute stroke codes may be activated for anisocoria, but how often these codes lead to a final stroke diagnosis or alteplase treatment is unknown. The purpose of this study was to assess the frequency of anisocoria in stroke codes that ultimately resulted in alteplase administration.Methods
We retrospectively assessed consecutive alteplase-treated patients from a prospectively-collected stroke registry between February 2015 and July 2018. Based on the stroke code exam, patients were categorized as having isolated anisocoria [A+(only)], anisocoria with other findings [A+(other)], or no anisocoria [A?]. Baseline demographics, stroke severity, alteplase time metrics, and outcomes were also collected.Results
Ninety-six patients received alteplase during the study period. Of the 94 who met inclusion criteria, there were 0 cases of A+(only). There were 9 cases of A+(other) (9.6%). A+(other) exhibited higher baseline National Institutes of Health (NIH) Stroke Scale scores compared to A? (17 versus 7; P?=?.0003), and no additional differences in demographics or alteplase time metrics. Final stroke diagnosis and other outcome measures were no different between A+(other) and A?. Of the A+ patients without pre-existing anisocoria, 5 of 6 (83%) had posterior circulation events or diffuse subarachnoid hemorrhage.Conclusions
In this exploratory analysis, zero patients with isolated anisocoria received alteplase treatment. Anisocoria as a part of the neurologic presentation occurred in 10% of alteplase patients, and was strongly associated with a posterior circulation event. Therefore, we conclude that anisocoria has a higher likelihood of leading to alteplase treatment when identified in the presence of other neurologic deficits. 相似文献175.
Ramya C. Mosarla Muthiah Vaduganathan Arman Qamar Javid Moslehi Gregory Piazza Robert P. Giugliano 《Journal of the American College of Cardiology》2019,73(11):1336-1349
Patients with active cancer are at an increased risk of arterial and venous thromboembolism (VTE) and bleeding events. Historically, in patients with cancer, low molecular weight heparins have been preferred for treatment of VTE, whereas warfarin has been the standard anticoagulant for stroke prevention in patients with atrial fibrillation (AF). More recently, direct oral anticoagulants (DOACs) have been demonstrated to reduce the risk of venous and arterial thromboembolism in large randomized clinical trials of patients with VTE and AF, respectively, thus providing an attractive oral dosing option that does not require routine laboratory monitoring. In this review, we summarize available clinical trial data and guideline recommendations, and outline a practical approach to anticoagulation management of VTE and AF in cancer. 相似文献
176.
177.
Toshiro Hara Rony Chanoch-Myers Nathan D. Mathewson Chad Myskiw Lyla Atta Lillian Bussema Stephen W. Eichhorn Alissa C. Greenwald Gabriela S. Kinker Christopher Rodman L. Nicolas Gonzalez Castro Hiroaki Wakimoto Orit Rozenblatt-Rosen Xiaowei Zhuang Jean Fan Tony Hunter Inder M. Verma Kai W. Wucherpfennig Itay Tirosh 《Cancer cell》2021,39(6):779-792.e11
- Download : Download high-res image (228KB)
- Download : Download full-size image
178.
179.
180.